Cargando…
Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics
Increasing evidence for the role of pharmacogenetics in treatment resistance to the antiplatelet agent clopidogrel has been gained during the last years. Apart from CYP2C19 genetic polymorphisms, nongenetic factors, particularly drug-drug interactions, age and other clinical characteristics influenc...
Autores principales: | Dahl, Marja-Liisa, Gunes, Arzu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034010/ https://www.ncbi.nlm.nih.gov/pubmed/27713279 http://dx.doi.org/10.3390/ph3040782 |
Ejemplares similares
-
Implications of Pharmacogenetic Testing for Clopidogrel Therapy in a Tertiary Healthcare Hospital in North India
por: Amarapalli, Jayachandra, et al.
Publicado: (2023) -
Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy
por: Alvitigala, Bhawani Yasassri, et al.
Publicado: (2020) -
The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
por: Amin, Arwa M., et al.
Publicado: (2017) -
Pharmacogenetic Selection of Volunteers Increases Stringency of Bioequivalence Studies; The Case of Clopidogrel
por: Garcés-Eisele, J., et al.
Publicado: (2014) -
Clinical, Pharmacokinetic, and Pharmacogenetic Determinants of Clopidogrel Resistance in Korean Patients with Acute Coronary Syndrome
por: Park, Kyoung-Jin, et al.
Publicado: (2011)